Epigenetic changes in tumor suppressor genes, P15, P16, APC-3 and E-cadherin in body fluid

Kaohsiung Journal of Medical Sciences

Volumn 23, Issue 10, 2007, Pages 498-503

  Chen, Mei Ling ^a   Chang, Julia Huei Mei ^a   Yeh, Kun Tu ^a   Chang, Ya Sian ^b   Chang, Jan Gowth ^b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Body fluid; Cytologist; Malignant cells; Methylation specific PCR; Tumor suppressor gene

Indexed keywords

PROTEIN P15; PROTEIN P16; UVOMORULIN;

ARTICLE; BODY FLUID; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; HUMAN; METHYLATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 36048953441     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(08)70007-X     Document Type: Article

References (35)

1. Bishop JM. The molecular genetics of cancer. Science 1987;235:305-11.
2. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-50.
3. Look AT. Oncogenic transcription factors in the human acute leukemia. Science 1997;278:1059-64.
4. Stanbridge EJ. Identifying tumor suppressor genes in human colorectal cancer. Science 1990;247:12-3.
5. Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. Hum Mol Genet 1996;5:1489-94.
6. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.
7. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997;13:444-9.
8. Razin A, Shemer R. DNA methylation in early development. Hum Mol Genet 1995;4:1751-5.
9. Razin A, Cedar H. DNA methylation and genomic imprinting. Cell 1994;77:473-6.
10. Laird PW, Jaenisch R. The role of DNA methylation in cancer genetics and epigenetics. Ann Rev Genet 1996;30:441-64.
11. Herman JG, Latif F, Weng Y, et al. Silencing of VHL tumor-suppressor gene by DNA methylation in renal Carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
12. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997;94:2545-50.
13. Lee WH, Morton RA, Epstein JI, et al. Cystidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7.
14. Yoshiura K, Kanai Y, Ochiai A, et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995;92:7416-9.
15. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
16. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
17. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31.
18. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer sternness and malignant behavior. Curr Opin Cell Biol 2007;19:150-8.
19. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007;17:45-51.
20. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
21. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006;7:667-77.
22. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-75.
23. Yeh KT, Chang JG, Lin TH, et al. Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer. Int J Oncol 2003;23:1001-7.
24. Lin SY, Yeh KT, Chen WT, et al. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep 2004;11:341-8.
25. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
26. Macleod K. Tumor suppressor genes. Curr Opin Genet Dev 2000;10:81-93.
27. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with CpG island methylator phenotype. Cancer Res 1999;59:5438-42.
28. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
29. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-9.
30. Shih MC, Yeh KT, Tang KP, et al. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 2006;45:732-40.
31. Samowitz WS, Slattery ML, Sweeney C, et al. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007;5:165-70.
32. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006;25:7531-7.
33. Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.
34. Debruyne P, Vermeulen S, Mareel M. The role of the E-cadherin/catenin complex in gastrointestinal cancer. Acta Gastroenterol Belg 1999;62:393-402.
35. Kanazawa T, Watanabe T, Kazama S, et al. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 2002;102:225-9.